CATALYST DOSSIER · UPDATED 2026-11-20
$MVST
tech · convergence -19 · conviction AVOID
Price & Live Quote Loading live quote & chart…
Practice trade tools Build a reference frame, save a practice trade, or preview a draft. No brokerage order is placed.
Paper trade unavailable: missing risk-bounded frame
Reference only. Not financial advice. No brokerage order is placed.
Why $MVST?
Quantitative
Revenue (CY2026Q2) : $87.3M (-446.0% YoY)
Net Income (CY2026Q2) : $-12.0M (+88.7% YoY)
Catalysts
Multi-spoke convergence : 8 convergent signals fired: finra_short, finra_regsho, xbrl_ni, auto_edgar_fulltext, auto_macro_adp_payrolls
Risks
Hard-to-borrow / FTD risk : Borrow rate 6.0%, distress score 30
Auditor change / restatement : substantial_doubt on
Bear case
Squeeze unwind : Short interest can compress before retail catches the move — entry timing critical
Sympathy basket (cerebro)
BZAI via semis r=+0.95 sympathetic (score 4)
FLEX via semis r=+0.95 sympathetic (score 4)
MMED via biotech r=+0.67 sympathetic (score 20)
CTGO via biotech r=+0.67 sympathetic (score 18)
RSVR via consumer r=+0.66 sympathetic (score 16)
DBGI via consumer r=+0.66 sympathetic (score 14)
Signals Firing
finra_short finra_regsho xbrl_ni auto_edgar_fulltext auto_macro_adp_payrolls auto_macro_bls_employment auto_macro_credit_spreads auto_macro_durable_goods
Pick Track Record Date List Next-day max run Next-day close Hit +2%? 2026-10-14 sec_top_gappers +8.2% +7.8% ✓ hit 2026-10-14 sec_top_moat_emerging +8.2% +7.8% ✓ hit 2026-10-13 sec_top_gappers +0.9% -5.0% — 2026-10-13 sec_top_moat_emerging +0.9% -5.0% — 2026-10-12 sec_top_gappers +2.5% +0.9% ✓ hit 2026-10-12 sec_top_moat_emerging +2.5% +0.9% ✓ hit
Lifetime: 4/6 wins · hit-rate 66.7% on +2% intraday
Sympathy Basket BZAI via semis · score 4 FLEX via semis · score 4 MMED via biotech · score 20 CTGO via biotech · score 18 RSVR via consumer · score 16 DBGI via consumer · score 14
Earnings Catalyst No recent earnings event.
Generate full earnings report
Auto-generated from public filings + tier-1 wires. Catalyst Edge publishes its picks
and its losses — see the
trust report and
methodology .
Not financial advice. Confirm independently before trading.